List of Excipients in API sulopenem etzadroxil and probenecid
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing sulopenem etzadroxil and probenecid
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | ORLYNVAH | sulopenem etzadroxil and probenecid | 81153-100 | ALUMINUM HYDROXIDE | 2034-10-25 |
| ITERUM THERAPEUTICS US LIMITED | ORLYNVAH | sulopenem etzadroxil and probenecid | 81153-100 | CELLULOSE, MICROCRYSTALLINE | 2034-10-25 |
| ITERUM THERAPEUTICS US LIMITED | ORLYNVAH | sulopenem etzadroxil and probenecid | 81153-100 | COCHINEAL | 2034-10-25 |
| ITERUM THERAPEUTICS US LIMITED | ORLYNVAH | sulopenem etzadroxil and probenecid | 81153-100 | CROSCARMELLOSE SODIUM | 2034-10-25 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for sulopenem etzadroxil and probenecid
Excipient focus: ALUMINUM HYDROXIDE
sulopenem etzadroxil and probenecid drug variants containing ALUMINUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing ALUMINUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
sulopenem etzadroxil and probenecid drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COCHINEAL
sulopenem etzadroxil and probenecid drug variants containing COCHINEAL
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing COCHINEAL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
sulopenem etzadroxil and probenecid drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
sulopenem etzadroxil and probenecid drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
sulopenem etzadroxil and probenecid drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LECITHIN, SOYBEAN
sulopenem etzadroxil and probenecid drug variants containing LECITHIN, SOYBEAN
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing LECITHIN, SOYBEAN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
sulopenem etzadroxil and probenecid drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
sulopenem etzadroxil and probenecid drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
sulopenem etzadroxil and probenecid drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
sulopenem etzadroxil and probenecid drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: XANTHAN GUM
sulopenem etzadroxil and probenecid drug variants containing XANTHAN GUM
| Company | Ingredient | NDC |
|---|---|---|
| ITERUM THERAPEUTICS US LIMITED | sulopenem etzadroxil and probenecid | 81153-100 |
| >Company | >Ingredient | >NDC |
sulopenem etzadroxil and probenecid drug variants not containing XANTHAN GUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch